Search International and National Patent Collections

1. (WO2017039358) PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TUMOR-PENETRATING PEPTIDE AND ANTI-ANGIOGENESIS AGENT ARE FUSED, FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES

Pub. No.:    WO/2017/039358    International Application No.:    PCT/KR2016/009801
Publication Date: Fri Mar 10 00:59:59 CET 2017 International Filing Date: Fri Sep 02 01:59:59 CEST 2016
IPC: A61K 38/16
A61K 38/10
A61K 38/17
A61K 39/395
C07K 19/00
Applicants: IL DONG PHARMACEUTICAL CO., LTD.
일동제약 주식회사
Inventors: KWON, Hyuk Sang
권혁상
KO, Jong-Hee
고종희
LEE, Yeong Min
이영민
JUNG, Hyei Yoon
정혜윤
YANG, Seok Woo
양석우
KANG, Jae-Hoon
강재훈
KIM, Yong-Sung
김용성
Title: PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TUMOR-PENETRATING PEPTIDE AND ANTI-ANGIOGENESIS AGENT ARE FUSED, FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES
Abstract:
The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti- vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.